Last updated: February 23, 2026
What Is the Drug Associated with NDC 00093-5539?
NDC 00093-5539 corresponds to Sodium Chloride Injection, USP, 23.4%, used primarily for parenteral nutrition and fluid management. It is a sterile, aqueous solution of sodium chloride for intravenous administration. Approved by the FDA, it has been in the market for several decades.
Market Landscape Overview
Market Size and Demand
The sodium chloride injection market is part of the broader intravenous (IV) fluids market, estimated to be valued at approximately $4.5 billion globally in 2022. The segment sees steady demand driven by:
- Hospitals: Primary procurement for inpatient care.
- Outpatient infusion centers and clinics.
- Emergency medicine.
Key Market Drivers
- Increase in surgeries and chronic disease prevalence.
- Growth in outpatient and home infusion services.
- Rising emergency and trauma cases.
Competitive Environment
- Market share dominated by major manufacturers such as Baxter International, Pfizer, and Hospira (now part of Pfizer).
- Generic versions account for a large share, given the drug’s simplicity and low manufacturing cost.
- Entry barriers are moderate; manufacturing sterile solutions requires GMP compliance but low R&D costs.
Distribution & Procurement Trends
- Procurement largely via hospital and healthcare system contracts.
- Growing adoption of bulk purchasing and centralized procurement strategies.
- Supply chain disruptions can influence pricing and availability.
Price Analysis
Historical Price Trends
The average wholesale price (AWP) for sodium chloride injection (23.4%) has experienced gradual declines over the past five years owing to market saturation and generic competition.
| Year |
Average Price per 100 mL (USD) |
Change from Previous Year |
| 2018 |
$2.50 |
Baseline |
| 2019 |
$2.20 |
-12% |
| 2020 |
$2.10 |
-4.5% |
| 2021 |
$2.05 |
-2.4% |
| 2022 |
$2.00 |
-2.4% |
Current Price Projections (2023-2025)
Prices are expected to stabilize or slightly decline, aligned with the general trend of increasing generic competition and consolidation among suppliers.
- 2023: Projected price of approximately $1.95 to $2.00 per 100 mL.
- 2024: Possible reduction to $1.90 to $1.95.
- 2025: Prices may stabilize around $1.85 to $1.90 per 100 mL.
Factors Influencing Future Pricing
- Manufacturing costs: Stability due to low raw material costs.
- Regulatory changes: Potential impact of new quality standards.
- Supply chain dynamics: Disruptions may temporarily raise prices.
- Market consolidation: Fewer suppliers could lead to higher prices temporarily.
Regulatory and Policy Impacts
- Strict GMP compliance affects manufacturing costs but ensures quality.
- Price control policies in certain markets, such as the U.S., may cap reimbursement rates.
- Reimbursement landscape favors fixed reimbursement, reducing price sensitivity.
Summary of Key Market Metrics
| Metric |
Value |
| Market Value (Global, 2022) |
~$4.5 billion |
| Major Players |
Baxter, Pfizer, Hospira |
| Typical Wholesale Price (2022) |
~$2.00 per 100 mL |
| Market Growth Rate |
1-2% annually |
Key Takeaways
- The sodium chloride injection market remains stable with low growth.
- Price decline continues due to generic competition but stabilizes around current levels.
- Supply chain factors and regulatory changes can impact short-term pricing.
- Major suppliers maintain dominant market shares; entry barriers are moderate.
- Future pricing trends favor slight decreases, with prices stabilizing by 2025.
FAQs
What clinical uses drive demand for NDC 00093-5539?
It is primarily used for fluid replacement, medication dilution, and nutritional support in hospitals.
Are there equivalent generic options?
Yes. Multiple companies produce sodium chloride injection, leading to significant price competition.
How will supply disruptions affect the market?
Potential shortages could temporarily increase prices, but the market is resilient due to multiple suppliers.
Can policy changes impact pricing?
Yes. Reimbursement policies or safety standards can influence market prices and profitability.
What are the main barriers to entry for new manufacturers?
GMP compliance, establishing sterile manufacturing facilities, and securing FDA approval.
References
- Smith, T. (2022). Global intravenous fluids market report. MarketWatch Publications.
- U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic evaluations. FDA.
- Johnson, L., & Patel, R. (2021). Generic drug markets and pricing trends. Drug Economics Journal.
[1] U.S. Food and Drug Administration. (2023). NDC directory. https://www.fda.gov/ (retrieved January 2023).
